Daniel Steiner

Senior Vice President, Targeted Radio Therapeutics Molecular Partners

Daniel Steiner, PhD, is Senior Vice President, Targeted Radio Therapeutics at Molecular Partners, where he leads the company’s efforts to develop next-generation targeted radiopharmaceuticals. Throughout his career at Molecular Partners, Daniel has contributed to the advancement of multiple therapeutic modalities, including targeted radiotherapeutics, multispecific immune cell engagers, and DARPin-based biologics in virology and ophthalmology. Daniel established the company’s DARPin discovery organization and helped develop key platform technologies, including approaches for systemic half-life extension. He earned his PhD at the University of Zurich under Prof. Andreas Plückthun and also studied at ETH Zurich and Imperial College London.

Seminars

Wednesday 24th February 2027
Understanding Dynamic Target Expression Beyond Receptor Density to Expand the Pool of Viable RLT Targets
9:00 am
  • Challenging static receptor-density thresholds to prevent promising therapeutic targets being ruled out too early
  • Understanding internalization & receptor replenishment to determine how lowerdensity targets can still deliver sufficient radiation to the tumor
  • Redefining “good enough” target expression to identify a broader range of viable targets for RLT development

Novel Target

Daniel Steiner, Speaker at 3rd TRP Target Selection & Drug Design Summit